Zhengye Biotechnology Holding Ltd(ZYBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 12 at 6:51 PM ET (Korea 11/13 08:51)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.21 | Insider Own | 74.09% | Shs Outstand | 29.7M | Perf Week | 8.7% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.7M | Perf Month | -1.96% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 0.29% | Short Float | 0.4% | Perf Quarter | -3.85% |
| Income | -0.01B | P/S | 2.76 | EPS this Y | - | Inst Trans | -1.27% | Short Ratio | 0.05 | Perf Half Y | 57.91% |
| Sales | 0.02B | P/B | 1.99 | EPS next 5Y | - | ROA | -14.98% | Short Interest | 0.03M | Perf YTD | 30.43% |
| Book/sh | 0.75 | P/C | 6 | EPS past 3/5Y | - | ROE | -26.09% | 52W High | -81.27% ($8.01) | Perf Year | -30.56% |
| Cash/sh | 0.25 | P/FCF | 25.77 | Sales past 3/5Y | -25.18% -16.43% | ROIC | -26.28% | 52W Low | 143.7% ($0.62) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -717.42% | Gross Margin | 20.41% | Volatility(W/M) | 8.61% 9.55% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 3.46 | Sales Y/Y TTM | -37.53% | Oper. Margin | -60.73% | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.8 | EPS Q/Q | -2195.59% | Profit Margin | -60.22% | RSI (14) | 54.6 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.14 | Sales Q/Q | -40.44% | SMA20 | 4.38% ($1.44) | Beta | -2.33 | Target Price | - |
| Payout | - | Debt/Eq | 0.3 | Earnings | - | SMA50 | 6.27% ($1.41) | Rel Volume | 0.05 | Prev Close | $1.52 |
| Employees | 269 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | 27.9% ($1.17) | Avg Volume(3M) | 0.60M | Price | $1.5 |
| IPO | 2025/1/7 | Option/Short | No/Yes | Trades | 96 | Volume | 29,333 | Change | -1.32% |
🐷 Zheng Yi Biotechnology () is a company that researches, develops, manufactures, and sells veterinary vaccines for livestock and companion animals in China. It holds a vaccine portfolio targeting pigs, cattle, sheep, poultry, dogs, and cats, and is expanding into the companion animal vaccine market.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
ZYBT has weak earning power
Of every $100 in sales, $60.73 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $276. Peers typically go for $164.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #62 of 83 in the industry
Based on market cap of $45M.
TLPH#59 Talphera Inc $54M PER - 
INCR#60 Intercure Ltd $52M PER - 
CTOR#61 Citius Oncology Inc $49M PER - ZYBT#62 Zhengye Biotechnology Holding Ltd $45M PER - 
SCYX#63 Scynexis Inc $33M PER - 
FAQ
What kind of company is ZYBT?
ZYBT belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ZYBT?
The market cap of ZYBT is approximately $45M, ranking 4,872 within its sector.
What is the 52-week high and low for ZYBT?
ZYBT has recorded a 52-week high of $8.01 and a low of $0.62.
